Summary & Overview

HCPCS Q5131: Adalimumab-aacf (Idacio), Biosimilar, 20 mg Injection

HCPCS Level II code Q5131 identifies a 20 mg dose of adalimumab-aacf (Idacio), a biosimilar injectable biologic. This code is used for billing the specific biosimilar product when administered to patients and matters nationally because biosimilar adoption affects drug spending, access to biologic therapies, and payer coverage policies across commercial insurers and Medicare. The code captures dosing and product identity essential for reimbursement, utilization tracking, and pharmacovigilance.

Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what Q5131 represents clinically and operationally, national implications for biosimilar use, and the types of benchmarks and policy issues typically associated with biosimilar injectable products. The publication highlights common billing practices tied to injectable biologics, payer coverage considerations, and where this code fits into service-line and outpatient drug administration workflows. Any unavailable input fields are noted as such; additional sections provide modifier guidance, associated taxonomies, and related coding where data is present. This summary is intended for billing managers, policy analysts, and clinicians seeking a clear, national-level briefing on HCPCS Level II code Q5131 and its role in biologic drug billing.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareQ5131HCPCS Level IIadalimumab-aacfIdaciobiosimilarinjectable biologicdrug administrationoutpatient infusionmedical billing

Billing Code Overview

HCPCS Level II code Q5131 denotes Injection, adalimumab-aacf (Idacio), biosimilar, 20 mg. The service is an injectable biologic therapy formulation of the adalimumab biosimilar Idacio provided as a 20 mg dose.

Service Type: Drug administration — injectable biologic

Typical Site of Service: Infusion/clinic or office-based injectable administration; may also be billed when the product is administered in outpatient facility settings.

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult with an autoimmune inflammatory condition such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or Crohn’s disease who is prescribed a biosimilar adalimumab product for subcutaneous maintenance therapy. The service Q5131 represents a 20 mg vial/syringe of adalimumab‑aacf (Idacio) provided as an administered or dispensed injectable biologic. Clinical workflow: patient arrives at an infusion/clinic or receives medication via specialty pharmacy; medication is verified against the medication order and patient allergies; appropriate documentation of indication, lot number, and expiration is completed; the medication is administered subcutaneously by a nurse or self‑administered by the patient with observation as required by facility policy; billing is generated using Q5131 for the biosimilar product, and relevant modifiers are appended when clinically applicable (for example, when services are discontinued, partially reduced, or when unusual procedural circumstances occur). Typical sites of service include outpatient clinic infusion centers, physician office/clinic, ambulatory surgical centers when applicable, and home administration under home health or specialty pharmacy support. Patient scenario example: a 54‑year‑old with seropositive rheumatoid arthritis with an inadequate response to methotrexate is transitioned to adalimumab‑aacf; medication is provided and administered in the rheumatology clinic with documentation of prior therapies, weight, lot number, and monitoring plan.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	When work required to provide the drug or related service is substantially greater than typically required (rare for standard drug administration; e.g., complex counseling, additional monitoring or documentation).
`23`	Unusual anesthesia	When general anesthesia or deep sedation is required for administration (very uncommon for subcutaneous injections).
`52`	Reduced services	When less than the full service was provided (e.g., partial dose administered due to intolerance).
`53`	Discontinued procedure	When administration is started but halted before completion for patient safety or adverse reaction.
`54`	Surgical care only	Not typically used for drug billing; applicable if surgical component billed separately and provider bills only surgical care.
`55`	Postoperative management only	Not typically used for standalone drug administration; included for completeness in multi‑service episodes.
`56`	Preoperative management only	Rarely applicable; use when only preoperative care is billed separate from drug administration.
`62`	Two surgeons	Use when two surgeons of different specialties are involved in a procedure related to the episode of care.
`AS`	Physician assistant, nurse practitioner, or clinical nurse specialist services for assistant at surgery	Not typically applicable to routine subcutaneous biologic administration; used if advanced practice clinician is acting as assistant at surgery.
`CO`	Items or services furnished to a Medicare beneficiary that are subject to a legal liability settlement or judgment	Use when third‑party settlement applies to the billed service.
`CQ`	Service furnished under a program or research protocol that has specific billing arrangements	Use when the biologic is provided under a study with unique billing rules.
`FX`	Service is rendered in an Ambulatory Surgical Center (ASC) but global package paid elsewhere	Use when billing coordination required between ASC and other payors for services related to the episode.
`FY`	Item or service paid under a fee schedule other than the physician fee schedule	Use when payment occurs under a different fee schedule applicable to the drug.
`QY`	Intravenous infusion or infusion pump provided by DMEPOS supplier	Use when infusion pump or DME supplier involvement is billed in conjunction with therapy.

Taxonomy Code	Specialty	Notes
`207R00000X`	Rheumatology	Rheumatologists frequently prescribe and oversee adalimumab biosimilars for inflammatory arthritis.
`207L00000X`	Gastroenterology	Gastroenterologists prescribe adalimumab biosimilars for inflammatory bowel disease management.
`208000000X`	Internal Medicine	Internists manage chronic systemic autoimmune disease and coordinate biologic therapy.
`363LP0800X`	Nurse Practitioner	NPs administer injections and manage biologic therapy in clinic and home settings.
`163W00000X`	Physician Assistant	PAs provide medication administration, patient education, and follow‑up for biologic therapies.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`M06.9`	Rheumatoid arthritis, unspecified	Common indication for adalimumab therapy when disease-modifying antirheumatic drugs are insufficient.
`M07.0`	Distal interphalangeal psoriatic arthropathy	Psoriatic arthritis subtypes treated with TNF inhibitors including adalimumab biosimilars.
`M45.9`	Ankylosing spondylitis, unspecified	Axial spondyloarthritis treated with anti‑TNF agents for active disease.
`K50.90`	Crohn's disease, unspecified, without complications	Crohn’s disease is an approved indication for adalimumab products for moderate to severe disease.
`K51.90`	Ulcerative colitis, unspecified, without complications	Ulcerative colitis is treated with biologic therapies including adalimumab for moderate to severe disease.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	Used to report the administration of a subcutaneous injection when the drug billing is separate or when a clinician documents an administration service in addition to the drug HCPCS.
`36415`	Collection of venous blood by venipuncture	Often performed prior to initiation or periodically during biologic therapy for baseline labs and monitoring.
`99001`	Handling and/or conveyance of specimen for transfer from the doctor’s office to a laboratory (local code varies) — Note: Medicare-specific codes may vary	Used in workflows where specimens are transported for lab testing related to therapy monitoring.
`G0008`	Administration of influenza virus vaccine (for influenza) — not directly related but example of vaccine administration code structure	Included as an example of administration coding structure; for biologic drug administration report `96372` typically.
`99406`	Smoking and tobacco use cessation counseling, intermediate	Behavioral counseling codes may be used in comprehensive care visits associated with chronic disease management; not specific to drug billing.